Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 48.

https://doi.org/10.1182/blood.V120.21.48.48

Published: 2012

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD

Blood (2012) 120 (21): 673.

https://doi.org/10.1182/blood.V120.21.673.673

Published: 2012

Journal Articles

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Blood (2011) 118 (21): 2576.

https://doi.org/10.1182/blood.V118.21.2576.2576

Published: 2011

Journal Articles

The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.

Ralf C. Bargou, MD, Peter Kufer, PhD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Rudolf Noppeney, MD, Andreas Viardot, MD, Georg Hess, MD, Gert Riethmueller, PhD, Dirk Reitsma, MD, Eugen Leo, MD, Carsten Reinhardt, MD, Gerhard Zugmaier, MD

Blood (2007) 110 (11): 2557.

https://doi.org/10.1182/blood.V110.11.2557.2557

Published: 2007

Journal Articles

Novel, 2 ND Generation Histone Deacetylase (HDAC) Inhibitor JNJ-26481585 Exhibits Potent Antitumor Activity Against Chronic Lymphocytic Leukemia Cells In-Vitro and Ex-Vivo .

Kurt Bommert, PhD, Stefan Knop, MD, Janine Arts, PhD, Peter King, PhD, Martin Page, PhD, Eugen Leo, MD, PhD, Ralf Bargou, MD

Blood (2007) 110 (11): 4679.

https://doi.org/10.1182/blood.V110.11.4679.4679

Published: 2007

Journal Articles

T Cell Responses during Long-Term Continuous Infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in Patients with Relapsed B-NHL: Data from Dose-Escalation Study MT103-104.

Matthias Klinger, Peter Kufer, MD, Petra Kirchinger, Ralf Lutterbüse, PhD, Eugen Leo, MD, Carsten Reinhardt, MD, Patrick Bäuerle, PhD, Ralf Bargou, MD

Blood (2006) 108 (11): 2725.

https://doi.org/10.1182/blood.V108.11.2725.2725

Published: 2006

Journal Articles

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).

Manfred Hensel, MD, Lars Scheuer, MD, Hans Salwender, MD, Juergen Finke, MD, Dieter Buerkle, MD, Heinz Albert Duerk, MD, Andreas Kaebisch, MD, Ralf Naumann, MD, Hans-Juergen Staiger, MD, Ingo Schmidt-Wolf, MD, Martin Kornacker, MD, Eugen Leo, MD, Joseph Fischer, MD, Anthony D. Ho, MD

Blood (2004) 104 (11): 4584.

https://doi.org/10.1182/blood.V104.11.4584.4584

Published: 2004

NARROW

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.

Novel, 2 ND Generation Histone Deacetylase (HDAC) Inhibitor JNJ-26481585 Exhibits Potent Antitumor Activity Against Chronic Lymphocytic Leukemia Cells In-Vitro and Ex-Vivo .

T Cell Responses during Long-Term Continuous Infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in Patients with Relapsed B-NHL: Data from Dose-Escalation Study MT103-104.

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).

Email alerts

ASH Publications

American Society of Hematology

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.

Novel, 2 ND Generation Histone Deacetylase (HDAC) Inhibitor JNJ-26481585 Exhibits Potent Antitumor Activity Against Chronic Lymphocytic Leukemia Cells In-Vitro and Ex-Vivo .

T Cell Responses during Long-Term Continuous Infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in Patients with Relapsed B-NHL: Data from Dose-Escalation Study MT103-104.

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only